AIM ImmunoTech Inc.
AIM
$9.21
$0.9110.96%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -24.35% | -15.84% | -1.55% | 19.64% | 23.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -24.35% | -15.84% | -1.55% | 19.64% | 23.72% |
| Cost of Revenue | -34.00% | -26.19% | 20.00% | -- | -27.54% |
| Gross Profit | -20.98% | -13.13% | -5.52% | -14.88% | 64.37% |
| SG&A Expenses | -44.71% | -34.59% | 46.46% | 66.48% | 70.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.93% | -37.91% | 18.80% | 44.49% | 58.08% |
| Operating Income | 47.06% | 38.05% | -18.97% | -44.68% | -58.33% |
| Income Before Tax | 51.13% | 40.20% | -15.18% | -44.98% | -61.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 51.13% | 40.20% | -15.18% | -44.98% | -61.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.13% | 40.20% | -15.18% | -44.98% | -61.35% |
| EBIT | 47.06% | 38.05% | -18.97% | -44.68% | -58.33% |
| EBITDA | 47.41% | 38.36% | -19.73% | -45.80% | -59.22% |
| EPS Basic | 61.56% | 47.94% | -10.42% | -42.16% | -58.95% |
| Normalized Basic EPS | 61.40% | 48.63% | -13.07% | -43.28% | -63.40% |
| EPS Diluted | 61.56% | 48.32% | -9.30% | -40.62% | -57.22% |
| Normalized Diluted EPS | 61.40% | 48.63% | -13.07% | -43.28% | -63.40% |
| Average Basic Shares Outstanding | 25.31% | 15.26% | 7.92% | 3.55% | 1.45% |
| Average Diluted Shares Outstanding | 25.31% | 15.26% | 7.92% | 3.55% | 1.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |